Table of Contents Author Guidelines Submit a Manuscript
Nursing Research and Practice
Volume 2010, Article ID 101749, 7 pages
http://dx.doi.org/10.1155/2010/101749
Review Article

Cardiovascular Risk Reduction with Renin-Angiotensin Aldosterone System Blockade

Stanford Cardiac Rehabilitation Program, 703 Welch Road, Suite F1, Palo Alto, CA 94304, USA

Received 2 October 2009; Revised 13 May 2010; Accepted 25 May 2010

Academic Editor: Patricia Davidson

Copyright © 2010 Nancy Houston Miller. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, “Cardiovascular diseases,” August 2009, http://www.who.int/topics/cardiovascular_diseases/en/.
  2. Centers for Disease Control, National Center for Health Statistics, August 2009, http://www.cdc.gov/nchs/fastats/.
  3. J. G. Trogdon, E. A. Finkelstein, I. A. Nwaise, F. K. Tangka, and D. Orenstein, “The economic burden of chronic cardiovascular disease for major insurers,” Health Promotion Practice, vol. 8, no. 3, pp. 234–242, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. American Heart Association, “Risk factors and coronary heart disease,” August 2009http://www.americanheart.org/presenter.jhtml?identifier=4726.
  5. A. V. Chobanian, G. L. Bakris, H. R. Black et al., “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report,” Journal of the American Medical Association, vol. 289, no. 19, pp. 2560–2572, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Kramkowski, A. Mogielnicki, and W. Buczko, “The physiological significance of the alternative pathways of angiotensin II production,” Journal of Physiology and Pharmacology, vol. 57, no. 4, pp. 529–539, 2006. View at Google Scholar · View at Scopus
  7. K. K. Parsons and T. M. Coffman, “The renin-angiotensin system: it's all in your head,” Journal of Clinical Investigation, vol. 117, no. 4, pp. 873–876, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. M. M. Ibrahim, “RAS inhibition in hypertension,” Journal of Human Hypertension, vol. 20, no. 2, pp. 101–108, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. V. J. Dzau, “Tissue renin-angiotensin system in myocardial hypertrophy and failure,” Archives of Internal Medicine, vol. 153, no. 8, pp. 937–942, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Buczko, T. Matys, I. Kucharewicz, and E. Chabielska, “The role of endothelium in antithrombotic effect of the renin-angiotensin system blockade,” Journal of Physiology and Pharmacology, vol. 50, no. 4, pp. 499–507, 1999. View at Google Scholar · View at Scopus
  11. R. Ardaillou, “Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects,” Current Opinion in Nephrology and Hypertension, vol. 6, no. 1, pp. 28–34, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. A. W. J. H. Dielis, M. Smid, H. M. H. Spronk et al., “The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems,” Hypertension, vol. 46, no. 6, pp. 1236–1242, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Bassenge, “Endothelial function in different organs,” Progress in Cardiovascular Diseases, vol. 39, no. 3, pp. 209–228, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Erdem, C. Usalan, I. C. Haznedaroglu et al., “Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension,” American Journal of Hypertension, vol. 12, no. 11 I, pp. 1071–1076, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. R. E. Schmieder, K. F. Hilgers, M. P. Schlaich, and B. M. Schmidt, “Renin-angiotensin system and cardiovascular risk,” Lancet, vol. 369, no. 9568, pp. 1208–1219, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. American Diabetes Association, “Complications of diabetes,” August 2009, http://www.diabetes.org/living-with-diabetes/complications/.
  17. W. C. Winkelmayer, Z. Zhang, S. Shahinfar, M. E. Cooper, J. Avorn, and B. M. Brenner, “Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes,” Diabetes Care, vol. 29, no. 10, pp. 2210–2217, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. J. H. Song, S. H. Cha, S. B. Hong, and D. H. Kim, “Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease,” Journal of Hypertension, vol. 24, no. 1, pp. S101–S106, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. X. R. Huang, W. Y. Chen, L. D. Truong, and H. Y. Lan, “Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease,” Journal of the American Society of Nephrology, vol. 14, no. 7, pp. 1738–1747, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Koka, W. Wang, X. R. Huang, S. Kim-Mitsuyama, L. D. Truong, and H. Y. Lan, “Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications,” Circulation, vol. 113, no. 10, pp. 1353–1360, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Li, J. Culman, H. Hörtnagl et al., “Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury,” FASEB Journal, vol. 19, no. 6, pp. 617–619, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. Z. Cao, M. E. Cooper, L. L. Wu et al., “Blockade of the renin-angiotensin and endothelin systems on progressive renal injury,” Hypertension, vol. 36, no. 4, pp. 561–568, 2000. View at Google Scholar · View at Scopus
  23. S. Yusuf, “Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients,” New England Journal of Medicine, vol. 342, no. 3, pp. 145–153, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. H. C. Gerstein, S. Yusuf, J. F. E. Mann et al., “Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy,” Lancet, vol. 355, no. 9200, pp. 253–259, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. K. M. Fox, “Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study),” Lancet, vol. 362, no. 9386, pp. 782–788, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Braunwald, M. J. Domanski, S. E. Fowler et al., “Angiotensin-converting-enzyme inhibition in stable coronary artery disease,” New England Journal of Medicine, vol. 351, no. 20, pp. 2058–2068, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Yusuf, K. K. Teo, J. Pogue et al., “Telmisartan, ramipril, or both in patients at high risk for vascular events,” New England Journal of Medicine, vol. 358, no. 15, pp. 1547–1559, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. J. N. Cohn and G. Tognoni, “A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure,” New England Journal of Medicine, vol. 345, no. 23, pp. 1667–1675, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. J. J. V. McMurray, J. Östergren, K. Swedberg et al., “Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial,” Lancet, vol. 362, no. 9386, pp. 767–771, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. M. A. Pfeffer, J. J. V. McMurray, E. J. Velazquez et al., “Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both,” New England Journal of Medicine, vol. 349, no. 20, pp. 1893–1906, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Braverman and J. Dedier, “Predictors of medication adherence for African American patients diagnosed with hypertension,” Ethnicity and Disease, vol. 19, no. 4, pp. 396–400, 2009. View at Google Scholar · View at Scopus
  32. R. Düsing, R. Handrock, S. Klebs, E. Tousset, and B. Vrijens, “Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE,” Journal of Hypertension, vol. 27, no. 4, pp. 894–901, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Vawter, X. Tong, M. Gemilyan, and P. W. Yoon, “Barriers to antihypertensive medication adherence among adults—United States, 2005,” Journal of Clinical Hypertension, vol. 10, no. 12, pp. 922–929, 2008. View at Publisher · View at Google Scholar · View at Scopus